|
cooler pusherthread hier, aviron, go! hier noch news vom freitag, die die hohe wahrscheinlichkeit der zulassung weiter untermauern (zudem wurde flumist in der vergangenheit nur aufgrund von mängeln im herstellungsverfahren nicht zugelassen, die sollten sich doch wohl beheben lassen!): Aviron Awarded Grant to Create Vaccine for Future Influenza Pandemics PR Newswire Friday September 29 8:35am MOUNTAIN VIEW, Calif., Sept. 29 /PRNewswire/ -- Aviron (Nasdaq: AVIR) today announced that it has received a $2.7 million Challenge Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to develop a vaccine to protect against possible pandemic influenza viruses. "The next pandemic has the potential to cause enormous casualties and social disruption. Aviron is pleased to have been selected by the NIAID to use our existing technology in a way that could help prepare us for the next pandemic," said C. Boyd Clarke, Aviron president and chief executive officer. Aviron also will commit $2.7 million over the three year duration of the grant. Challenge Grants are milestone-driven awards, meaning recipients must achieve predetermined product goals during the development process. Under the grant, Aviron will develop vaccine candidates against potential pandemic strains of influenza. The vaccine candidates will utilize the intranasal delivery technology currently used for FluMist(TM), Aviron`s investigational intranasal influenza vaccine. In principle, nasal delivery of influenza vaccines could be particularly useful in quickly vaccinating large numbers of people, including children, who many consider the primary spreaders of the flu. An influenza pandemic can occur when a strain of the influenza virus changes enough so that humans have no natural immunity to it. Influenza pandemics have occurred three times during the twentieth century. The deadliest was the 1918 "Spanish flu" which resulted in more than 20 million deaths worldwide, more than any other event in the twentieth century except world wars. In the United States alone, the CDC estimates that the next influenza pandemic could infect up to 200 million people, cause between 88,000 and 300,000 deaths and result in economic losses of up to $166 billion. Aviron is a biopharmaceutical company based in Mountain View, California, focused on the prevention of disease through innovative vaccine technology. Actual results may differ materially from the forward-looking statements contained in this release. Factors that could cause actual results to differ include, but are not limited to, failure to validate the manufacturing process, facilities or equipment for the company`s nasal influenza vaccine, and the assessment by regulatory agencies that the company`s future license applications for its nasal influenza vaccine are incomplete or inadequate to approve the product for marketing to one or more target populations. Additional information concerning factors that could cause such a difference is contained in Aviron`s SEC filings, including its S-3 Registration Statement and Annual Report on Form 10-K for the year ended December 31, 1999. To receive an index and copies of recent press releases, call Aviron`s News-On-Call toll-free fax service, 800-758-5804, extension 114000. Additional information about the company can be located at http://www.aviron.com . Source:Aviron Contact: Media, John Bluth, 650-919-3716, or Asha Jennings, 650-919-1429, both of Aviron; or Camela Stuby of Fleishman-Hillard, 212-453-2000, for Aviron; or Investors, John Bluth, 650-919-3716, or Fred Kurland, 650-919-6666, both of Aviron Source: PR Newswire |
|
| aus der Diskussion: | AVIRON gegen Morphosys: 100% mehr Gewinnchancen !!! |
| Autor (Datum des Eintrages): | märchenland (02.10.00 14:05:07) |
| Beitrag: | 26 von 26 (ID:1972869) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |